Home Table of Contents

§ 13-3501. Definitions

West's Annotated Code of MarylandHealth--GeneralEffective: June 1, 2017

West's Annotated Code of Maryland
Health--General
Title 13. Miscellaneous Health Care Programs (Refs & Annos)
Subtitle 35. CO-Prescribing of Opioid Overdose Reversal Drugs (Refs & Annos)
Effective: June 1, 2017
MD Code, Health - General, § 13-3501
§ 13-3501. Definitions
In general
(a) In this subtitle the following words have the meanings indicated.
Co-prescribing
(b) “Co-prescribing” means, with respect to an opioid overdose reversal drug, the practice of prescribing the drug in conjunction with an opioid prescription for a patient at an elevated risk of overdose.
Opioid overdose reversal drug
(c) “Opioid overdose reversal drug” means naloxone or a similarly acting and equally safe drug that is approved by the federal Food and Drug Administration for the treatment of a known or suspected opioid overdose.

Credits

Added by Acts 2017, c. 571, § 1, eff. June 1, 2017; Acts 2017, c. 572, § 1, eff. June 1, 2017.
MD Code, Health - General, § 13-3501, MD HEALTH GEN § 13-3501
Current with all legislation from the 2023 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
End of Document